Cite
MLA Citation
Anna K. Stalder et al.. “Biomarker‐guided clinical development of the first‐in‐class anti‐inflammatory FPR2/ALX agonist ACT‐389949.” British journal of clinical pharmacology, vol. 83, n.d., pp. 476–486. http://access.bl.uk/ark:/81055/vdc_100041767483.0x000035